NCT05924776View on ClinicalTrials.gov

Plasmodium Immunotherapy for Advanced Ovarian Cancer

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 20, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

March 30, 2029

Conditions
Advanced Ovarian Cancer
Interventions
BIOLOGICAL

Plasmodium immunotherapy

Inoculation 1-5 × 10\^6 Plasmodium vivax once

Trial Locations (1)

Unknown

The Third Affiliated Hospital of Southern Medical University, Guangzhou

All Listed Sponsors
collaborator

The Third Affiliated Hospital of Southern Medical University

OTHER_GOV

lead

CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.

INDUSTRY

NCT05924776 - Plasmodium Immunotherapy for Advanced Ovarian Cancer | Biotech Hunter | Biotech Hunter